Evidence map›Paper›PMID 33067910›Full record

ArticleBirth defects research2021

Developmental and reproductive safety evaluation of AV7909 anthrax vaccine candidate in rats.

Eve Mylchreest, M Autumn Smiley, Jeff D Ballin, Bruna Blauth, Jeffry Shearer, Joshua Reece, Boris Ionin, Vladimir Savransky

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Birth defects research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eve MylchreestBattelle, West Jefferson, Ohio, USA.
M Autumn SmileyBattelle, West Jefferson, Ohio, USA.
Jeff D BallinBattelle, Aberdeen, Maryland, USA.
Bruna BlauthEmergent BioSolutions Inc., Gaithersburg, Maryland, USA.
Jeffry ShearerEmergent BioSolutions Inc., Gaithersburg, Maryland, USA.
Joshua ReeceEmergent BioSolutions Inc., Gaithersburg, Maryland, USA.
Boris IoninEmergent BioSolutions Inc., Gaithersburg, Maryland, USA.
Vladimir SavranskyEmergent BioSolutions Inc., Gaithersburg, Maryland, USA.ORCID 0000-0002-6458-2690
Emergent BioSolutions (United States) · USBattelle · US

Funding

Department of Health and Human Services, Biomedical Advanced Research and Development Authority HHSO100201600030C
6 · The paper itself

Abstract

The AV7909 vaccine, consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and the immunostimulatory Toll-like receptor 9 agonist oligodeoxynucleotide adjuvant CPG 7909. The purpose of this research was to evaluate the potential maternal, reproductive, and developmental toxicity of AV7909 in rats to support licensure for use in women of childbearing potential. Groups of first generation (F

Indexed as

AnthraxAnthrax VaccinesAnimalsAntibodies, NeutralizingFemalePregnancyRatsRats, Sprague-DawleyReproductionAnthrax VaccinesAntibodies, Neutralizinganthrax vaccineAV7909developmental toxicityratreproductive toxicity

Identifiers

PMID33067910
PMCPMC7821328
OpenAlexW3093032902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.